CDK6 and leukemia: Some CDKs can be considered oncogenic, e.g., CDK4 in familial melanoma (Zhao et al., 2012), CDK6 in MLL-rearranged leukemia (Placke et al., 2014), and CDK8 in colon cancer (Firestein et al., 2008).